[Anti-TNF alpha therapy: a risk factor for legionella infection].
Lagier
J C
JC
Andriamanantena
D
D
Damiano
J
J
Dot
J M
JM
Chaudier
B
B
Margery
J
J
D018501:Antirheumatic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage / Q000009:adverse effects*; D007876:Legionellosis / Q000175:diagnosis*; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D009894:Opportunistic Infections / Q000175:diagnosis*; D018124:Receptors, Tumor Necrosis Factor / Q000008:administration & dosage; D012307:Risk Factors; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000068800:Etanercept; D008727:Methotrexate